Bayer AG & Monsanto v. Lovett: GMO Patent Suit Dismissed With Prejudice
Bayer AG and Monsanto Technology LLC brought a patent infringement action against individual defendant Patrick R. Lovett in Missouri’s Eastern District, asserting two foundational agri-biotech patents covering chloroplast transit peptides and the soybean event MON89788. The case closed with a voluntary dismissal with prejudice after 400 days — before the defendant even filed an answer.
Bayer and Monsanto drop GMO patent suit against individual grower
Filed on 1 November 2023 in the Eastern District of Missouri before Judge Henry Edward Autrey, this infringement action saw Bayer AG and co-plaintiff Monsanto Technology LLC assert two biotechnology patents against individual defendant Patrick R. Lovett. The asserted patents — US7838729B2, directed to chloroplast transit peptides enabling efficient DMO enzyme targeting, and US9944945B2, covering soybean event MON89788 and its detection methods — are core to Bayer/Monsanto’s proprietary herbicide-tolerant soybean technology stack.
The action closed on 5 December 2024 when plaintiffs filed a notice of voluntary dismissal with prejudice under Federal Rule of Civil Procedure 41(a)(1)(A)(i). Because the defendant had not served an answer or a motion for summary judgment, no court order was required to effect the dismissal. A dismissal with prejudice is a final adjudication on the merits, meaning the plaintiffs are permanently barred from re-filing the same claims against Lovett on the same patents.
The 400-day duration and the absence of any responsive pleading from the defendant suggests the case may have resolved through private settlement, a licensing arrangement, or a strategic decision by plaintiffs to withdraw enforcement — though the public record is silent on the specific driver. The with-prejudice designation is notable: it forecloses future litigation on these patents against this defendant, indicating the plaintiffs were confident the dispute would not recur or that a binding resolution had been reached outside the courtroom.
Filing to Dismissed with Prejudice in 400 days
400 days from filing to closure — resolved before defendant answered
Dismissed with prejudice: what the Rule 41 filing means for both parties
Rule 41(a)(1)(A)(i): self-executing dismissal, no judge required
Under Fed. R. Civ. P. 41(a)(1)(A)(i), a plaintiff may dismiss an action without a court order by filing a notice before the opposing party serves an answer or a motion for summary judgment. Lovett had done neither, so the notice was self-executing. The ‘with prejudice’ election — beyond the rule’s default — converts the voluntary act into a final judgment on the merits, permanently extinguishing the plaintiffs’ claims on these patents against this defendant.
Self-executing, no court order neededBayer and Monsanto walk away — but close the door permanently
By choosing dismissal with prejudice, Bayer and Monsanto surrendered the right to sue Lovett again on US7838729B2 and US9944945B2. This typically signals either a private resolution — such as a grower licensing agreement or compliance commitment — or a deliberate decision that continued litigation is not commercially warranted. The patents themselves remain valid and enforceable against all other parties; only the claims against Lovett specifically are extinguished.
Patents survive; claims against Lovett closedLovett avoids judgment — but faces permanent record of the suit
Lovett was never required to answer and no adverse judgment was entered against him. The with-prejudice dismissal protects him from any future lawsuit by Bayer or Monsanto on the same two patents. However, the public filing record remains. For individual growers or seed dealers, a high-profile IP action from Bayer/Monsanto — even one that resolves early — may have reputational or compliance implications that extend beyond the courtroom outcome.
No judgment entered; future suit barredGMO trait enforcement: corporate giants still actively police individual use
This case is consistent with Bayer/Monsanto’s longstanding strategy of asserting patent rights against individual growers to deter seed saving and unauthorised replanting of patented transgenic varieties. The early dismissal with prejudice — before any merits adjudication — suggests the enforcement goal may have been compliance rather than damages. For the agri-biotech sector, it signals that even cases against individuals serve a deterrence function in protecting high-value GMO trait portfolios.
Deterrence-driven enforcement patternFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Bayer AG | Company | Agri-biotech conglomerate — holder of US7838729B2 and US9944945B2Search in Eureka ↗ |
| Co-Plaintiff | Monsanto Technology, LLC | Company | Search in Eureka ↗ |
| Defendant | Patrick R. Lovett | Individual | Individual defendant Patrick R. Lovett; no counsel of record entered appearanceSearch in Eureka ↗ |
| Plaintiff counsel | Daniel C. Cox | Attorney | Counsel for Bayer AGSearch in Eureka ↗ |
| Plaintiff law firm | Thompson Coburn LLP (St Louis) | Law Firm | Representing Bayer AGSearch in Eureka ↗ |
| Presiding judge | Judge Henry Edward Autrey | Judge | Missouri Eastern District CourtSearch in Eureka ↗ |
Official order — verbatim text
The dismissal notice invokes Rule 41(a)(1)(A)(i) explicitly and designates the dismissal as ‘with prejudice’ — a plaintiff-elected upgrade beyond the rule’s without-prejudice default. The phrasing that ‘no Court Order is necessary’ reflects the rule’s mechanics: the right to self-execute lapses once a defendant answers or moves for summary judgment. Lovett having done neither preserves the plaintiffs’ unilateral authority. The with-prejudice designation is the legally significant element: it operates as a final adjudication on the merits, barring re-litigation of these specific patent claims against Lovett by these plaintiffs in any forum.
US7838729B2 & US9944945B2 — GMO trait patents at the core of the dispute
US7838729B2 (application US11/758659) protects chloroplast transit peptide sequences that enable efficient targeting of the dicamba monooxygenase (DMO) enzyme to chloroplasts in transgenic plants — a foundational mechanism underlying Bayer/Monsanto’s dicamba-tolerant crop technology. US9944945B2 (application US14/539923) covers soybean event MON89788, a specific herbicide-tolerant soybean transformation event, and the molecular detection methods used to identify its presence in plant material or seed lots. Both patents sit at the infrastructure layer of the Roundup Ready 2 Yield and dicamba-tolerance trait stack.
Together, these patents represent significant commercial value: MON89788 underlies one of the most widely planted soybean varieties in North America, and the chloroplast transit peptide technology is broadly applicable across multiple crop species. Competitors or innovators working on herbicide-tolerant soybean traits, dicamba-tolerance mechanisms, or transgenic crop detection assays face non-trivial freedom-to-operate risk from this portfolio. The patents’ breadth and Bayer/Monsanto’s active enforcement posture — including against individual growers — make them high-priority targets for FTO and landscape analysis.
Should you run an FTO against US7838729B2 and US9944945B2?
Any R&D team or agri-input company working on dicamba-tolerant transgenic crops, chloroplast-targeting peptide sequences, or herbicide-tolerant soybean event development should treat these two patents as mandatory FTO targets. The chloroplast transit peptide claims in US7838729B2 are potentially broad enough to implicate any transgenic program using DMO-based herbicide tolerance, not just soybean. US9944945B2’s detection method claims are directly relevant to seed testing labs, trait purity assurance programs, and event-specific diagnostic kit developers.
PatSnap Eureka’s FTO Search Agent enables R&D and IP teams to map claim scope against product pipelines, identify prior art that may limit enforceability, and surface design-around pathways — all within a single workflow. For agri-biotech teams operating near Bayer/Monsanto’s trait portfolio, proactive FTO analysis against US7838729B2 and US9944945B2 is a defensible first step before committing to development or commercialisation of herbicide-tolerant soybean or DMO-targeting technology.
Run a freedom-to-operate analysis on US7838729B2 to assess your product’s exposure
Run FTO in Eureka →Similar agri-biotech GMO patent enforcement cases in US district courts
Cases involving Bayer/Monsanto’s herbicide-tolerant crop and GMO trait patents litigated in US district courts, including individual grower enforcement actions.
What this case signals for the agri-biotech GMO IP enforcement landscape
Bayer and Monsanto’s swift, with-prejudice exit reveals the compliance logic underlying individual grower enforcement actions.
With-prejudice dismissals before answer often signal off-record resolution
When a corporate plaintiff like Bayer/Monsanto voluntarily dismisses with prejudice before the defendant has even answered, it typically signals a negotiated resolution — a grower licensing agreement, a cease-and-desist compliance, or a structured settlement. IP teams monitoring agri-biotech enforcement should treat early with-prejudice exits as probable indicators of private commercial resolution rather than evidentiary weakness.
MON89788 and chloroplast transit peptide patents remain active enforcement tools
This dismissal does not affect the validity or enforceability of US7838729B2 or US9944945B2. Both patents remain live weapons in Bayer/Monsanto’s portfolio. Companies developing herbicide-tolerant soybean traits or competing DMO-targeting technologies should conduct FTO analysis against these patents before commercialisation in the US market.
Bayer v Patrick — key questions answered
A with-prejudice dismissal operates as a final judgment on the merits, permanently barring Bayer and Monsanto from re-filing the same patent claims against Lovett. Choosing this designation — beyond Rule 41(a)(1)(A)(i)’s default — typically signals that the underlying dispute has been resolved to the plaintiffs’ satisfaction, whether through a licensing agreement, compliance commitment, or other private arrangement.
Two patents were asserted: US7838729B2, covering chloroplast transit peptides for efficient targeting of the DMO enzyme in transgenic plants, and US9944945B2, covering soybean event MON89788 and methods for its detection. Both are core to Bayer/Monsanto’s herbicide-tolerant soybean technology platform.
Rule 41(a)(1)(A)(i) allows a plaintiff to voluntarily dismiss an action without a court order by filing a notice before the defendant serves an answer or a motion for summary judgment. The dismissal is self-executing. In this case, the plaintiffs elected to make it ‘with prejudice,’ converting the voluntary act into a permanent bar against re-filing the same claims against the same defendant.
No. The dismissal with prejudice extinguishes only the plaintiffs’ claims against Patrick R. Lovett specifically. Both US7838729B2 and US9944945B2 remain valid, in force, and enforceable against any other party. The dismissal contains no merits adjudication and does not constitute a challenge to or limitation of the patents’ scope.
Bayer/Monsanto maintains a documented program of enforcing its seed patent rights against individual growers to deter unauthorised seed saving, replanting of patented transgenic varieties, and distribution of infringing plant material. Individual enforcement actions serve a systemic deterrence function — signalling to the broader grower population that IP compliance is actively monitored. Early resolution, as here, is consistent with the program’s compliance-focused rather than damages-focused objective.
PatSnap Eureka searches patents and litigation data to answer instantly.